In just over a decade, PPARγ has evolved from modestbeginnings as a simple regulator of adipogenesis to become a keytherapeutic target in the fight against the 21st century epidemicsof obesity, insulin resistance, and the metabolic syndrome. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.